尼龙和抗凝剂:弥合与理性治疗的差距
Syntia Nusanti1, Andhika Rachman2, Brigitta Marcia Budihardja3
1Doctoral Program in Medical Science, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia and Neuro-ophthalmology Division, Ophthalmology Department, Hematology and Medical Oncology Division.
Journal of Ayub Medical College, Abbottabad : JAMC
|November 29, 2024
概括
包括华法林在内的抗凝药疗法可以改善非动脉炎前部缺血性视觉神经病变 (NAION) 和高凝血的患者的视觉功能. 这种治疗有可能减轻流量不足,并有助于在受影响的个体中改善临床效果.
科学领域:
- 眼科医生 眼科 眼科
- 神经学 神经学
- 血管医学 血管医学
背景情况:
- 非动脉炎前部缺血性视神经病变 (NAION) 是一种复杂的疾病,其机制尚不清楚,治疗选择有限.
- 在NAION中,代谢风险因素经常与高凝血状态重叠,这表明存在潜在的联系.
- 调查抗凝治疗在NAION中的作用对于了解其对血管和视觉结果的影响至关重要.
研究的目的:
- 评估抗凝剂治疗对NAION患者血管功能和视觉结果的影响.
- 为了比较NAION患者与没有高凝血治疗的抗凝血剂治疗之间的结果.
主要方法:
- 一项前性干预研究,涉及NAION患者的两个组:高凝血和非高凝血.
- 所有参与者都接受了阿司匹林;高凝血组也接受了华法林.
- 在治疗前和治疗后,通过OCTA评估血管参数 (毛细血管 perfusion,流量指数) 和视觉功能 (视觉敏度,视野).
主要成果:
- 两组都显示了毛细血管 perfusion (CP) 和流量指数 (FI) 的显著下降.
- 接受华法林的高凝血组在视野参数 (MD,VFI) 中表现出显著的改善.
- 虽然大多数高凝血患者的情况有所改善,但非高凝血组的变化很小.
结论:
- 在NAION患者中,抗凝固药物治疗可能有助于减缓血管流量不足的进展.
- 临床增强和改善视觉功能是NAION抗凝剂治疗的潜在好处,特别是在高凝血患者中.
相关概念视频
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
623
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
623
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.2K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.2K
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
455
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
455
01:13Therapeutic Index
4.1K
The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...
4.1K
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
469
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
469